Recurrent Gastrointestinal Stromal Tumors in the Imatinib Mesylate Era: Treatment Strategies for an Incurable Disease
Introduction. Recurrence of gastrointestinal stromal tumors (GISTs) after surgical resection and imatinib mesylate (IM) adjuvant therapy poses a significant treatment challenge. We present the case of a patient who underwent surgical resection after recurrence and review the current literature regar...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2017/8349090 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849403576882823168 |
|---|---|
| author | Rebecca M. Platoff William F. Morano Luiz Marconcini Nicholas DeLeo Beth L. Mapow Michael Styler Wilbur B. Bowne |
| author_facet | Rebecca M. Platoff William F. Morano Luiz Marconcini Nicholas DeLeo Beth L. Mapow Michael Styler Wilbur B. Bowne |
| author_sort | Rebecca M. Platoff |
| collection | DOAJ |
| description | Introduction. Recurrence of gastrointestinal stromal tumors (GISTs) after surgical resection and imatinib mesylate (IM) adjuvant therapy poses a significant treatment challenge. We present the case of a patient who underwent surgical resection after recurrence and review the current literature regarding treatment. Case Presentation. A 58-year-old man with a large intra-abdominal jejunal GIST was treated with complete surgical resection followed by IM. The patient experienced disease recurrence 3.5 years later and underwent IM dose escalation and reresection. Conclusion. Current strategies to treat recurrent GIST include dose escalation, modifying adjuvant tyrosine kinase inhibitor therapy, and surgery. High-level evidence will be required to better define the combinatory roles of tyrosine kinase inhibitor therapy, guided by molecular profiling, and surgery in the management of recurrent GIST. |
| format | Article |
| id | doaj-art-8e54a6e334d8453e92ec17c5023d5b13 |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-8e54a6e334d8453e92ec17c5023d5b132025-08-20T03:37:15ZengWileyCase Reports in Oncological Medicine2090-67062090-67142017-01-01201710.1155/2017/83490908349090Recurrent Gastrointestinal Stromal Tumors in the Imatinib Mesylate Era: Treatment Strategies for an Incurable DiseaseRebecca M. Platoff0William F. Morano1Luiz Marconcini2Nicholas DeLeo3Beth L. Mapow4Michael Styler5Wilbur B. Bowne6Department of Surgery, Drexel University College of Medicine, Philadelphia, PA, USADepartment of Surgery, Drexel University College of Medicine, Philadelphia, PA, USADepartment of Medicine, Division of Hematology/Oncology, Drexel University College of Medicine, Philadelphia, PA, USADepartment of Surgery, Drexel University College of Medicine, Philadelphia, PA, USADepartment of Pathology and Laboratory Medicine, Drexel University College of Medicine, Philadelphia, PA, USADepartment of Medicine, Division of Hematology/Oncology, Drexel University College of Medicine, Philadelphia, PA, USADepartment of Surgery, Drexel University College of Medicine, Philadelphia, PA, USAIntroduction. Recurrence of gastrointestinal stromal tumors (GISTs) after surgical resection and imatinib mesylate (IM) adjuvant therapy poses a significant treatment challenge. We present the case of a patient who underwent surgical resection after recurrence and review the current literature regarding treatment. Case Presentation. A 58-year-old man with a large intra-abdominal jejunal GIST was treated with complete surgical resection followed by IM. The patient experienced disease recurrence 3.5 years later and underwent IM dose escalation and reresection. Conclusion. Current strategies to treat recurrent GIST include dose escalation, modifying adjuvant tyrosine kinase inhibitor therapy, and surgery. High-level evidence will be required to better define the combinatory roles of tyrosine kinase inhibitor therapy, guided by molecular profiling, and surgery in the management of recurrent GIST.http://dx.doi.org/10.1155/2017/8349090 |
| spellingShingle | Rebecca M. Platoff William F. Morano Luiz Marconcini Nicholas DeLeo Beth L. Mapow Michael Styler Wilbur B. Bowne Recurrent Gastrointestinal Stromal Tumors in the Imatinib Mesylate Era: Treatment Strategies for an Incurable Disease Case Reports in Oncological Medicine |
| title | Recurrent Gastrointestinal Stromal Tumors in the Imatinib Mesylate Era: Treatment Strategies for an Incurable Disease |
| title_full | Recurrent Gastrointestinal Stromal Tumors in the Imatinib Mesylate Era: Treatment Strategies for an Incurable Disease |
| title_fullStr | Recurrent Gastrointestinal Stromal Tumors in the Imatinib Mesylate Era: Treatment Strategies for an Incurable Disease |
| title_full_unstemmed | Recurrent Gastrointestinal Stromal Tumors in the Imatinib Mesylate Era: Treatment Strategies for an Incurable Disease |
| title_short | Recurrent Gastrointestinal Stromal Tumors in the Imatinib Mesylate Era: Treatment Strategies for an Incurable Disease |
| title_sort | recurrent gastrointestinal stromal tumors in the imatinib mesylate era treatment strategies for an incurable disease |
| url | http://dx.doi.org/10.1155/2017/8349090 |
| work_keys_str_mv | AT rebeccamplatoff recurrentgastrointestinalstromaltumorsintheimatinibmesylateeratreatmentstrategiesforanincurabledisease AT williamfmorano recurrentgastrointestinalstromaltumorsintheimatinibmesylateeratreatmentstrategiesforanincurabledisease AT luizmarconcini recurrentgastrointestinalstromaltumorsintheimatinibmesylateeratreatmentstrategiesforanincurabledisease AT nicholasdeleo recurrentgastrointestinalstromaltumorsintheimatinibmesylateeratreatmentstrategiesforanincurabledisease AT bethlmapow recurrentgastrointestinalstromaltumorsintheimatinibmesylateeratreatmentstrategiesforanincurabledisease AT michaelstyler recurrentgastrointestinalstromaltumorsintheimatinibmesylateeratreatmentstrategiesforanincurabledisease AT wilburbbowne recurrentgastrointestinalstromaltumorsintheimatinibmesylateeratreatmentstrategiesforanincurabledisease |